Lucid Diagnostics

Lucid Diagnostics, Inc. develops medical testing devices. It is a commercial-stage medical diagnostics technology company which focuses on gastroesophageal reflux disease (GERD), acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The firm's products include EsoCheck is a cell collection device that is designed to collect cells of a targeted region of the esophagus without the need for endoscopy and EsoGuard is a laboratory developed test which analyzes methylated biomarkers. The company was founded on May 8, 2018 and is headquartered in New York, NY.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lucid Diagnostics excels in Q4, eyes growth through precancer detection

Lucid Diagnostics (LUCD) demonstrated robust performance in Q4 2022, focusing on growth, financial stability, and strategic initiatives for precancer detection.
The company's strengths lie in strong revenue potential, innovative testing models, and a proactive approach to securing payer coverage and expanding its market reach.
While facing challenges in cash management and sales team tenure, Lucid Diagnostics has opportunities to drive growth through geographic expansion, high-risk group engagement, and data-driven payer strategies.

Lucid Diagnostics reports robust Q1 performance and growth opportunities

Lucid Diagnostics showed strong performance with increased tests and financial security in Q1 2023.
The company's focus on early precancer detection and large target market are key strengths.
Challenges include improving payment collections and securing in-network contracts.
Opportunities lie in expanding outreach efforts and engaging with payers for coverage.

Lucid Diagnostics reports robust Q2 performance and eyes sustained growth

Lucid Diagnostics delivered a strong Q2 performance with notable revenue growth and operational improvements.
While facing challenges in revenue recognition and payer engagement, the company's focus on clinical utility studies and high-volume events presents growth opportunities.
With a solid financial position and a strategic approach to market access, Lucid is poised for sustained growth and increased market penetration.

Lucid Diagnostics (LUCD) reports stellar Q3 growth and eyes market expansion

Lucid Diagnostics (LUCD) demonstrated strong performance in Q3 2023, marked by substantial revenue and test volume growth. The company's strategic initiatives, financial stability, and focus on market access position it for continued success. While challenges in managing expenses persist, Lucid's opportunities for expansion and engagement with key stakeholders pave the way for future growth and profitability.

Lucid Diagnostics reports stellar Q4 results and eyes market expansion

Lucid Diagnostics (LUCD) showcased robust financial performance and strategic initiatives in Q4 2023, driving revenue growth and market expansion.
While facing challenges such as significant operating expenses and uncertainties in reimbursement processes, Lucid is well-positioned to capitalize on opportunities for revenue realization and market access.
With a focus on clinical validity, engagement with payers, and exclusive product rights, Lucid demonstrates a strong competitive advantage and potential for sustained growth in the diagnostic market.

Lucid Diagnostics excels in Q1 2024, poised for market expansion

Lucid Diagnostics delivered strong financial performance in Q1 2024, showcasing revenue growth, robust margins, and a strengthened balance sheet.
The company's focus on market access strategies, innovative diagnostics, and revenue cycle improvements positions them for future success.
While facing challenges such as pending adjudications and international expansion limitations, Lucid is well-positioned to capitalize on opportunities in healthcare partnerships and market awareness.
Overall, Lucid's commitment to driving commercial potential and enhancing cancer detection technologies underpins their growth trajectory and shareholder value creation.

Lucid Diagnostics reports robust revenue growth and navigates reimbursement challenges

Lucid Diagnostics demonstrated strong revenue growth momentum driven by record test volumes and positive clinical data.
While facing reimbursement challenges, the company's proactive approach to market access and partnerships positions them for future success.
Maintaining a healthy cash position and focusing on operational efficiency are key strengths that support Lucid's growth trajectory.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company was founded by Lishan Aklog on May 8, 2018 and is headquartered in New York, NY.

NEW YORK--(BUSINESS WIRE)---- $LUCD--PAVmed subsidiary Lucid Diagnostics launches EsoGuard telemedicine program in partnership with UpScriptHealth.

PAVmed Subsidiary Lucid Diagnostics Launches EsoGuard Telemedicine Program in Partnership with UpScriptHealth

NEW YORK--(BUSINESS WIRE)---- $LUDC--Lucid Diagnostics to present at Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum.

Lucid Diagnostics to Present at Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

NEW YORK--(BUSINESS WIRE)---- $LUCD--PAVmed and Lucid provide business update and preliminary third quarter 2021 financial results.

PAVmed and Lucid Provide Business Update and Preliminary Third Quarter 2021 Financial Results

NEW YORK--(BUSINESS WIRE)---- $LUCD #LUCD--PAVmed and Lucid to Hold Joint Business Update Conference Call on November 16, 2021 at 4:30PM EDT.

PAVmed and Lucid to Hold Joint Business Update Conference Call on November 16, 2021

NEW YORK--(BUSINESS WIRE)---- $LUCD--Lucid Diagnostics' EsoGuard Esophageal DNA Test wins “Diagnostics Innovation of the Year” award.

Lucid Diagnostics' EsoGuard Esophageal DNA Test Wins “Diagnostics Innovation of the Year” Award

NEW YORK--(BUSINESS WIRE)---- $LUCD--Lucid Diagnostics appoints Suman Verma MD, PhD as Chief Scientific Officer.

ADDING MULTIMEDIA Lucid Diagnostics Appoints Suman Verma MD, PhD as Chief Scientific Officer

Lucid Diagnostics Appoints Suman Verma MD, PhD as Chief Scientific Officer

NEW YORK--(BUSINESS WIRE)---- $LUCD--Lucid Diagnostics announces closing of Nasdaq Initial Public Offering.

Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering

Unfortunately, today is a very red day for investors who got in on the recent LUCD stock IPO, with shares of this stock down more than 17%. The post LUCD Stock IPO: 7 Things to Know as Lucid Diagnostics Starts Trading Today appeared first on InvestorPlace.

LUCD Stock IPO: 7 Things to Know as Lucid Diagnostics Starts Trading Today

GitLab

IHS Holding Ltd

Gitlab, a software developer, popped, but telecom tower operator IHS Holding and Lucid Diagnostics, a medical device designer, dropped.

3 Companies Opened for Trading Today. Here's How They Did.

Lucid Diagnostics Inc. LUCD, -20.64% was jeered in its public debut, as the New York-based medical diagnostics technology company's stock opened on the Nasdaq 8.9% below its initial public offering price, and kept falling. The company raised $70.0 million, as it sold 5.0 million shares in its IPO, which priced overnight at $14 a share, at the bottom of the expected range of between $14 and $16 a share.

Lucid Diagnostics stock opens about 9% below the IPO price, and keeps falling

PAVmed

NEW YORK--(BUSINESS WIRE)---- $LUCD--Lucid Diagnostics announces pricing of Initial Public Offering.

Lucid Diagnostics Announces Pricing of Initial Public Offering

News for Lucid Diagnostics Stock (LUCD)